Manufacturinglive biotherapeutic product is both technically challenging and financiallydemanding; as a result, innovator firms are becoming increasingly reliant oncontract service providers to access specialized facilities and optimizeoverall costs.
RootsAnalysis is pleased to announce the publication of its recent study, titled, “LiveBiotherapeutic Products and Microbiome Contract Manufacturing Market,2020-2030: Focus on Active Pharmaceutical Ingredients and Finished DosageForms, 2020-2030.”
Thereport features an extensive study of the current landscape and futureopportunities related to contract services for microbiome therapeutics. Thestudy features an in-depth analysis, highlighting the capabilities of a diverseset of contract service providers, including CMOs and CDMOs. Amongst otherelements, the report includes:
· A detailed review of the overall landscape ofcompanies offering contract services for manufacturing of microbiometherapeutics.
· A list of companies with in-housemanufacturing facilities for microbiome therapeutics.
· Elaborate profiles of key industry players(large and mid-sized companies, established before 2000) based in NorthAmerica, Europe and Asia-Pacific.
· An assessment of microbiome contractmanufacturing capability in different regions.
· A list of nearly 50 microbiome-focused drugdevelopers that are anticipated to partner with contract manufacturers.
· A detailed clinical trial analysis of morethan 150 completed, ongoing and planned studies of various microbiometherapeutics sponsored by both industry and non-industry players.
· An estimate of the overall, installedcapacity for manufacturing of microbiome therapeutics, taking intoconsideration the capabilities of various stakeholders.
· An informed estimate of the annual clinicaldemand for microbiome therapeutics, taking into account the target patientpopulation in ongoing and planned clinical trials of microbiome therapeutics,sponsored by both industry and non-industry players.
· A qualitative analysis, highlighting thevarious factors that need to be taken into consideration by microbiometherapeutics developers while deciding whether to manufacture their respectiveproducts in-house or engage the services of a CMO.
· A review of the varied microbiome-focusedinitiatives of big pharma players.
Requestfor Customization: https://www.rootsanalysis.com/reports/306/request-customization.html
Adetailed market forecast, featuring analysis of the current and projectedfuture opportunity across key market segments (listed below):
Typeof Product Manufactured
· Active Pharmaceutical Ingredients (APIs)
· Finish Drug Formulations (FDFs)
Typeof Type of Formulation
· Solid Formulations
· Oral Liquids
· Injectables
· Others
Scaleof Operation
· Clinical
· Commercial
CompanySize
· Small-sized
· Mid-sized
· Large
KeyGeographical Regions
· North America
· Europe
· Asia-Pacific and Rest of the World
Keycompanies covered in the report
· Biose®
· BJP Laboratories
· Capsugel (acquired by Lonza)
· Cerbios-Pharma
· Cobra Biologics (acquired CognateBioservices)
· Inpac Probiotics
· Paragon Bioservices (a unit of CatalentBiologics)
· UAS Labs
RequestPDF Sample:
https://www.rootsanalysis.com/reports/306/request-sample.html
AboutRoots Analysis
RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
AlsoVisit Our Latest Publication
In Silico / Computer-Aided DrugDiscovery Services Market
Antibody Contract Manufacturing Market
Biopharma Contract Manufacturing Market
Cell Therapy Manufacturing Market
